Permission was obtained from the Ministry of Health of the Russian Federation to conduct three Phase III clinical trials to assess the efficacy and safety of a new oral medicine for patients with moderate or severe Crohn's disease, sponsored by the pharmaceutical company Selgene, Switzerland.
Our partners
